Opinion|Videos|December 16, 2024
Demographics and Baseline Characteristics Across Spesolimab Dose Groups
Panelists discuss how the Effisayil 2 trial included diverse patient demographics across different spesolimab dose groups, with baseline characteristics such as age, disease severity, and history of GPP flares influencing the treatment outcomes and safety data.
Advertisement
Episodes in this series
Advertisement
Related to this article
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.
ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.
LRM will evaluate injectable rhPDGF-BB as a regenerative approach to infraorbital hollowing in a randomized phase 2b trial.
ORKA-001 achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B trial of moderate-to-severe psoriasis.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Stratman discusses individualized eczema care, expanding treatment options, and the potential of precision medicine to guide therapy.
Advertisement
Advertisement
Trending on Dermatology Times
1
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
2
ORKA-001 Achieves 61% Complete Skin Clearance in Psoriasis
3
ATI-052 Shows Rapid Improvements in Atopic Dermatitis
4
FDA Revises TB Evaluation Guidance for SKYRIZI
5